Evorpacept is under clinical development by ALX Oncology and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Relapsed Acute Myeloid Leukemia have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Evorpacept’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
evorpacept is under development for the treatment of advanced solid tumors including colorectal cancer, indolent and aggressive B-cell non-Hodgkin lymphoma, gastro-esophageal junction cancers, acute myeloid leukemia, relapsed/refractory acute myeloid leukemia, epithelial ovarian, endometrial cancer, urothelial cancers, recurrent head and neck cancer squamous cell carcinoma and relapsed or refractory, higher risk myelodysplastic syndrome, non-Hodgkin lymphoma including mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma, metastatic gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma, metastatic transitional (urothelial) tract cancer. It is administered intravenously. The drug candidate is a fusion protein containing high affinity CD47 binding domain of SIRPalpha linked to an inactive Fc region of human immunoglobulin.
It was also under development for breast cancer, leiomyosarcoma, non-small cell lung cancer, pancreatic, peritoneal, appendiceal, thymic cancers.
ALX Oncology overview
ALX Oncology (ALXO) is an immune-oncology company that discovers and develops treatments for cancer and hematology indications. It is investigating its lead product candidate evorpacept (ALX148), a CD47 blocker for the treatment of hematologic and solid tumors; and ALTA-002, a SIRPa toll-like receptor agonist antibody conjugate (TRAAC) targeting advanced cancer. The company is also evaluating its lead candidate in combination with other agents against head and neck squamous cell carcinoma, gastric, urothelial, and breast cancer, myelodysplastic syndromes, acute myeloid leukemia, and non-Hodgkin’s lymphoma. ALXO is headquartered in South San Francisco, California, the US.
For a complete picture of Evorpacept’s drug-specific PTSR and LoA scores, buy the report here.